Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00274859
Recruitment Status : Unknown
Verified May 2007 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 11, 2006
Last Update Posted : July 24, 2008
Information provided by:
National Cancer Institute (NCI)

January 10, 2006
January 11, 2006
July 24, 2008
August 2005
Not Provided
Objective response rate
Not Provided
Complete list of historical versions of study NCT00274859 on Archive Site
  • Clinical benefit
  • Tolerability
  • Progression-free
  • Overall survival
Not Provided
Not Provided
Not Provided
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
Multicenter Phase II Study Evaluating Gemcitabine and Oxaliplatin in the Treatment of Patients Suffering From Metastatic Breast Cancer Who Are Not Candidates For Treatment With Antracyclines and Taxanes

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

PURPOSE: This phase II trial is studying how well giving gemcitabine together with oxaliplatin works in treating patients with metastatic cancer who cannot receive anthracycline or taxane therapy.



  • Determine the objective response rate in patients with metastatic cancer not amenable to anthracycline or taxane therapy treated with gemcitabine hydrochloride and oxaliplatin.


  • Determine the clinical benefit and tolerability of this regimen in these patients.
  • Determine the progression-free and overall survival of patients treated with this regimen.

OUTLINE: This is an open-label, multicenter study.

Patients receive gemcitabine hydrochloride IV over 100 minutes on day 1 and oxaliplatin IV over 2 hours on day 2. Treatment repeats every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study.

Phase 2
Masking: None (Open Label)
Primary Purpose: Treatment
Unspecified Adult Solid Tumor, Protocol Specific
  • Drug: gemcitabine hydrochloride
  • Drug: oxaliplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Not Provided
Not Provided
Not Provided


  • Histologically confirmed cancer

    • Metastatic disease
  • Measurable metastatic disease ≥ 1 cm by spiral CT scan and/or cutaneous lesion ≥ 2 cm
  • Not a candidate for anthracycline or taxane chemotherapy
  • No brain metastases


  • ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%
  • Life expectancy > 12 weeks
  • Neutrophil count > 1,000/mm^3
  • Platelet count > 100,000/mm^3
  • Alkaline phosphatase < 5 times upper limit of normal (ULN)
  • Bilirubin < 1.5 times ULN
  • Creatinine < 1.5 times ULN OR creatinine clearance > 30 mL/min
  • SGOT and SGPT < 3 times ULN (5 times ULN if liver metastases present)
  • No pre-existing neuropathy
  • Not pregnant or nursing
  • No uncontrolled hypercalcemia
  • No familial, social, geographical, or psychological condition that would preclude study treatment
  • No other malignancy that is not considered cured


  • No prior chemotherapy for metastatic disease, including anthracyclines or taxanes
  • Prior hormonal therapy allowed
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Not Provided
GERCOR - Multidisciplinary Oncology Cooperative Group
Not Provided
Study Chair: Joseph Gligorov, MD Hopital Tenon
National Cancer Institute (NCI)
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP